Go to deals
Healthcare

Tem Group has been acquired by Instrumentation Laboratory

The shareholders of Tem Group (TEM) have sold the company to Instrumentation Laboratory (IL). Financial details have not been disclosed.

TEM is a global leader in in-vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems. With a direct sales force in seven markets, including the USA, TEM has consistently achieved above market growth in the PBM market. In hospital trauma and surgical patients with clinically significant bleeding, ROTEM whole blood analyzers provide a rapid differential diagnosis of coagulopathies. This supports targeted transfusion and coagulation factor concentrate therapy and, as a result, is key to PBM programs. PBM is a multi-disciplinary, evidence-based medical concept, optimizing a patient’s own blood volume, minimizing blood loss and thereby significantly reducing or avoiding blood transfusion.

IL, founded in 1959 and based in Bedford, Massachusetts, is a worldwide developer, manufacturer and distributor of in-vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include critical care systems, hemostasis systems and information management systems. IL is an integral part of the Werfen family of companies which distributes its products by a direct sales force in North America and Werfen organizations around the globe.

"A passion for innovation, leading systems and extensive knowledge in PBM, make TEM a perfect complement to our focus, commitment, and leadership in hemostasis and critical care IVD," said Ramon Benet, CEO at IL. "IL and our global Werfen organizations are ideally positioned to maximize the potential of the ROTEM product line, which intersects our existing business and presents synergies in our core competencies and customer call points. Most importantly, ROTEM systems share the same ultimate benefit of all our products, to help customers reduce overall hospital costs, while improving patient care."

Oaklins' team in Switzerland advised the seller in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

Dr. Roberto  Tracia

Dr. Roberto Tracia

Partner

Bern, Switzerland
Oaklins Switzerland
 Daniel  Vogel

Daniel Vogel

Director

Zurich, Switzerland
Oaklins Switzerland
 David  Zürrer

David Zürrer

Director

Basel, Switzerland
Oaklins Switzerland

Related deals

BlijWerkt has been acquired by Mentha Capital
Business Support Services | Healthcare | Private Equity

BlijWerkt has been acquired by Mentha Capital

Gilde Healthcare Partners has sold BlijWerkt Groep B.V. to Mentha Capital.

Learn more
Lead Healthcare has successfully raised financing provided by Rabobank
Healthcare

Lead Healthcare has successfully raised financing provided by Rabobank

Lead Healthcare has successfully raised financing provided by Rabobank.

Learn more
ERBC (ex CERB) has acquired RTC
Healthcare

ERBC (ex CERB) has acquired RTC

The European Research Biology Center (ERBC) has acquired the Research Toxicology Center (RTC).

Learn more